 Omar Khan
Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bariatric Surgery | 2 | 2020 | 193 | 0.930 |
Why?
| | Global Health | 2 | 2016 | 329 | 0.760 |
Why?
| | International Educational Exchange | 1 | 2016 | 12 | 0.510 |
Why?
| | Fractures, Bone | 1 | 2020 | 392 | 0.460 |
Why?
| | Education, Medical, Undergraduate | 1 | 2016 | 176 | 0.430 |
Why?
| | Maternal Death | 1 | 2013 | 11 | 0.420 |
Why?
| | Schools, Medical | 1 | 2013 | 132 | 0.380 |
Why?
| | Maternal Health Services | 1 | 2013 | 95 | 0.380 |
Why?
| | Quality Assurance, Health Care | 1 | 2013 | 318 | 0.360 |
Why?
| | Kidney Transplantation | 1 | 2016 | 672 | 0.320 |
Why?
| | Clinical Trials as Topic | 2 | 2015 | 1004 | 0.310 |
Why?
| | Endpoint Determination | 1 | 2009 | 76 | 0.310 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2009 | 130 | 0.300 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2009 | 73 | 0.300 |
Why?
| | Health Promotion | 1 | 2013 | 719 | 0.270 |
Why?
| | Pelizaeus-Merzbacher Disease | 1 | 2006 | 3 | 0.260 |
Why?
| | RNA, Small Interfering | 4 | 2019 | 587 | 0.250 |
Why?
| | Neuromyelitis Optica | 2 | 2017 | 129 | 0.230 |
Why?
| | Endothelium, Vascular | 2 | 2021 | 901 | 0.220 |
Why?
| | Iron-Binding Proteins | 1 | 2021 | 40 | 0.180 |
Why?
| | Multiple Sclerosis | 3 | 2010 | 436 | 0.170 |
Why?
| | Network Meta-Analysis | 1 | 2020 | 9 | 0.170 |
Why?
| | Friedreich Ataxia | 1 | 2021 | 75 | 0.170 |
Why?
| | Cellular Senescence | 1 | 2021 | 181 | 0.160 |
Why?
| | Vascular Remodeling | 1 | 2021 | 192 | 0.160 |
Why?
| | Hypertension, Pulmonary | 2 | 2021 | 1894 | 0.150 |
Why?
| | Glycine | 1 | 2019 | 165 | 0.150 |
Why?
| | Bayes Theorem | 1 | 2020 | 375 | 0.150 |
Why?
| | Mitochondrial Proteins | 1 | 2019 | 248 | 0.130 |
Why?
| | Capacity Building | 1 | 2016 | 59 | 0.120 |
Why?
| | Cultural Competency | 1 | 2016 | 82 | 0.120 |
Why?
| | Gastrectomy | 1 | 2016 | 100 | 0.120 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2015 | 36 | 0.120 |
Why?
| | Obesity | 2 | 2020 | 2883 | 0.120 |
Why?
| | Dextrans | 1 | 2015 | 82 | 0.120 |
Why?
| | Humans | 18 | 2021 | 129650 | 0.110 |
Why?
| | Developing Countries | 1 | 2016 | 287 | 0.110 |
Why?
| | Brain | 1 | 2006 | 2679 | 0.110 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 764 | 0.100 |
Why?
| | Gene Silencing | 1 | 2014 | 190 | 0.100 |
Why?
| | Antibodies | 1 | 2015 | 398 | 0.100 |
Why?
| | Nanostructures | 1 | 2014 | 100 | 0.100 |
Why?
| | Interpersonal Relations | 1 | 2016 | 392 | 0.100 |
Why?
| | International Cooperation | 1 | 2013 | 174 | 0.100 |
Why?
| | Obesity, Morbid | 1 | 2016 | 240 | 0.100 |
Why?
| | Graft Rejection | 1 | 2016 | 598 | 0.100 |
Why?
| | Gene Expression | 2 | 2014 | 1472 | 0.100 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 336 | 0.100 |
Why?
| | Program Evaluation | 1 | 2016 | 875 | 0.090 |
Why?
| | Transfection | 1 | 2014 | 911 | 0.090 |
Why?
| | Social Environment | 1 | 2013 | 292 | 0.090 |
Why?
| | Laparoscopy | 1 | 2016 | 451 | 0.090 |
Why?
| | Myocardium | 1 | 2016 | 980 | 0.090 |
Why?
| | Weight Loss | 1 | 2016 | 734 | 0.090 |
Why?
| | Immunologic Factors | 2 | 2010 | 231 | 0.090 |
Why?
| | Lipids | 1 | 2014 | 625 | 0.080 |
Why?
| | Education, Medical | 1 | 2013 | 244 | 0.080 |
Why?
| | Neuroprotective Agents | 1 | 2010 | 122 | 0.080 |
Why?
| | Major Histocompatibility Complex | 1 | 2010 | 230 | 0.080 |
Why?
| | Twins, Monozygotic | 1 | 2010 | 210 | 0.080 |
Why?
| | Sample Size | 1 | 2009 | 116 | 0.080 |
Why?
| | Research Design | 1 | 2015 | 1044 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2016 | 2391 | 0.080 |
Why?
| | Stroke | 1 | 2017 | 1071 | 0.080 |
Why?
| | Macrophages | 1 | 2016 | 1480 | 0.080 |
Why?
| | Secondary Prevention | 1 | 2009 | 218 | 0.070 |
Why?
| | Genome, Human | 1 | 2010 | 393 | 0.070 |
Why?
| | MicroRNAs | 1 | 2014 | 678 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 335 | 0.070 |
Why?
| | United States | 2 | 2016 | 13903 | 0.070 |
Why?
| | Fabry Disease | 1 | 2006 | 1 | 0.070 |
Why?
| | Curriculum | 1 | 2013 | 917 | 0.060 |
Why?
| | Mice | 6 | 2021 | 16937 | 0.060 |
Why?
| | Mice, Inbred C57BL | 4 | 2019 | 5440 | 0.060 |
Why?
| | Demyelinating Diseases | 1 | 2006 | 84 | 0.060 |
Why?
| | Epigenesis, Genetic | 1 | 2010 | 613 | 0.060 |
Why?
| | Female | 7 | 2021 | 68776 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2019 | 4083 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2010 | 3083 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 2012 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 2 | 2010 | 2282 | 0.060 |
Why?
| | Myelin Sheath | 1 | 2006 | 160 | 0.060 |
Why?
| | Lung Neoplasms | 2 | 2014 | 2344 | 0.050 |
Why?
| | Heart Failure | 1 | 2016 | 2150 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2010 | 2708 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2021 | 2871 | 0.050 |
Why?
| | Endothelial Progenitor Cells | 1 | 2021 | 20 | 0.050 |
Why?
| | Animals | 6 | 2021 | 35361 | 0.040 |
Why?
| | Adult | 4 | 2019 | 35576 | 0.040 |
Why?
| | Mice, Transgenic | 2 | 2016 | 2119 | 0.040 |
Why?
| | Male | 5 | 2021 | 63681 | 0.040 |
Why?
| | Iron-Sulfur Proteins | 1 | 2019 | 28 | 0.040 |
Why?
| | Cell Respiration | 1 | 2019 | 98 | 0.040 |
Why?
| | Haplotypes | 2 | 2010 | 475 | 0.040 |
Why?
| | Mice, 129 Strain | 1 | 2016 | 87 | 0.030 |
Why?
| | Mutation | 2 | 2019 | 3717 | 0.030 |
Why?
| | RNAi Therapeutics | 1 | 2015 | 4 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 1033 | 0.030 |
Why?
| | Middle Aged | 1 | 2016 | 31154 | 0.030 |
Why?
| | RNA, Neoplasm | 1 | 2014 | 88 | 0.030 |
Why?
| | Triazines | 1 | 2014 | 38 | 0.030 |
Why?
| | HIV | 1 | 2015 | 226 | 0.030 |
Why?
| | ras Proteins | 1 | 2014 | 144 | 0.030 |
Why?
| | Nanotechnology | 1 | 2014 | 122 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 259 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1434 | 0.030 |
Why?
| | Cisplatin | 1 | 2014 | 300 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2014 | 312 | 0.020 |
Why?
| | HeLa Cells | 1 | 2014 | 608 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2015 | 478 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 1206 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2014 | 638 | 0.020 |
Why?
| | Glatiramer Acetate | 1 | 2010 | 18 | 0.020 |
Why?
| | Allelic Imbalance | 1 | 2010 | 8 | 0.020 |
Why?
| | INDEL Mutation | 1 | 2010 | 15 | 0.020 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2014 | 511 | 0.020 |
Why?
| | Calcineurin Inhibitors | 1 | 2010 | 68 | 0.020 |
Why?
| | Chronic Disease | 1 | 2016 | 1720 | 0.020 |
Why?
| | Nanoparticles | 1 | 2014 | 374 | 0.020 |
Why?
| | Interferon-beta | 1 | 2010 | 89 | 0.020 |
Why?
| | CpG Islands | 1 | 2010 | 152 | 0.020 |
Why?
| | HLA-DRB1 Chains | 1 | 2010 | 108 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2015 | 815 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2010 | 257 | 0.020 |
Why?
| | Heterozygote | 1 | 2010 | 272 | 0.020 |
Why?
| | Breast | 1 | 2010 | 153 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2010 | 224 | 0.020 |
Why?
| | DNA Copy Number Variations | 1 | 2010 | 170 | 0.020 |
Why?
| | Adjuvants, Immunologic | 1 | 2010 | 221 | 0.020 |
Why?
| | Genetics, Population | 1 | 2010 | 200 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4063 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4897 | 0.020 |
Why?
| | Quantitative Trait Loci | 1 | 2010 | 355 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 2014 | 898 | 0.020 |
Why?
| | Alleles | 1 | 2010 | 845 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2010 | 640 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2014 | 3215 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2015 | 1928 | 0.020 |
Why?
| | Adolescent | 2 | 2019 | 20393 | 0.020 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 1052 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2017 | 7086 | 0.020 |
Why?
| | Infant | 1 | 2019 | 9024 | 0.020 |
Why?
| | DNA Methylation | 1 | 2010 | 607 | 0.010 |
Why?
| | Peptides | 1 | 2010 | 925 | 0.010 |
Why?
| | Child, Preschool | 1 | 2019 | 10517 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2010 | 1056 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 2061 | 0.010 |
Why?
| | Young Adult | 1 | 2019 | 12426 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2010 | 3381 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 2073 | 0.010 |
Why?
| | HIV Infections | 1 | 2015 | 2720 | 0.010 |
Why?
| | Cohort Studies | 1 | 2010 | 5420 | 0.010 |
Why?
| | Child | 1 | 2019 | 20883 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2010 | 2142 | 0.010 |
Why?
| | Lung | 1 | 2010 | 3930 | 0.010 |
Why?
|
|
Khan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|